CA-JUNIPER-NETWORKS
8.3.2023 08:01:40 CET | Business Wire | Press release
Juniper Networks, (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Shaare Zedek Medical Center, Jerusalem’s largest and fastest growing multi-disciplinary medical center, has embarked on total digital transformation of operations to provide superior experiences and exceptional care to its patients using Juniper’s data center solutions.
Shaare Zedek is a leading research and teaching hospital, running 30 departments and 70 outpatient clinics, which provide innovative treatments and therapies to one million patients per year. The hospital is also a model for large-scale emergency medicine and a leader in applying AI to patient care. Using Juniper® technology, the hospital built state-of-the-art data centers on its two campuses to ensure the availability of life-critical systems and applications for uninterrupted patient care and robust data analysis to guide the best courses of treatment.
News Highlights:
- Shaare Zedek uses the Juniper Apstra software to automate data center network operations, which leads to improved patient experiences. Apstra assures the network is running as intended and alerts the IT team if brownouts or deviations occur. The IT team also uses Apstra to manage changes, maintenance and updates.
- With Juniper Apstra software, Shaare Zedek has been able to deploy its network fabric faster, guarantee data center uptime with network visibility and automation, streamline network operations, resolve issues more quickly and reduce total cost of ownership for its data center network.
- The hospital operates 24x7 and cannot shut down the data center for maintenance to switches, clusters, etc. With Juniper Apstra, Shaare Zedek can fully automate changes in real time and assure continuous operations.
- The Juniper Networks® QFX5120 Switches form the data center network fabric, delivering 100-Gbps of capacity to support clinical and administrative applications and massive data stores.
- Shaare Zedek worked with Oasis Technologies, a Juniper Elite Plus partner, to create the optimal data center architecture, working on the design, validation and testing to ensure that the Juniper solutions met Shaare Zedek’s strategic operational and technical goals.
Supporting Quotes:
“Digital health is transforming patient care at Shaare Zedek. Our data center operations must ensure the continuous availability of our life-critical systems and applications. Juniper provides the foundation of our reliable data center with next-level automation that assures best practice and consistency, to intent from initial design to everyday operations.”
- Shimi Ben Baruch, Vice President & Chief Technology Officer, Shaare Zedek Medical Center
“The network plays a vital role in keeping a modern organization healthy. It allows organizations to scale and support new applications and technologies that can assist in driving better patient outcomes and experiences. Juniper Apstra provides high performance technologies for Shaare Zedek Medical Center to ensure that it is fully prepared for continued digital acceleration.”
- Gos Hein van de Wouw, Vice President, Enterprise, EMEA, Juniper Networks
Additional Resources:
- Shaare Zedek Medical Center: Success Story
- Follow Juniper Networks online: Facebook | Twitter | LinkedIn
- Juniper Blogs and Community: J-Net
About Juniper Networks
Juniper Networks is dedicated to dramatically simplifying network operations and driving superior experiences for end users. Our solutions deliver industry-leading insight, automation, security and AI to drive real business results. We believe that powering connections will bring us closer together while empowering us all to solve the world’s greatest challenges of well-being, sustainability and equality. Additional information can be found at Juniper Networks (www.juniper.net) or connect with Juniper on Twitter, LinkedIn and Facebook.
Juniper Networks, the Juniper Networks logo, Juniper, Junos, and other trademarks listed here are registered trademarks of Juniper Networks, Inc. and/or its affiliates in the United States and other countries. Other names may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005125/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom